China Approves Genzyme's Rizabrutinib for Adult ITP
The National Medical Products Administration of China has recently approved the marketing of rizabrutinib tablets (trade name: Sailizhi), a Class 1 innovative drug submitted by Genzyme Corporation. The drug is indicated for adult patients with persistent or chronic primary immune thrombocytopenia (ITP) who have previously shown an inadequate response to, or intolerance of, treatments such as corticosteroids and immunoglobulins.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 50/100 and 70% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.